Noteworthy Price Action: Does Agenus Inc Have Any Gas After Today’s Big Increase?

Noteworthy Price Action: Does Agenus Inc Have Any Gas After Today's Big Increase?

The stock of Agenus Inc (NASDAQ:AGEN) is a huge mover today! About 716,661 shares traded hands. Agenus Inc (NASDAQ:AGEN) has declined 12.85% since April 4, 2016 and is downtrending. It has underperformed by 13.94% the S&P500.
The move comes after 6 months positive chart setup for the $347.56M company. It was reported on Nov, 4 by Barchart.com. We have $11.53 PT which if reached, will make NASDAQ:AGEN worth $656.89 million more.

Agenus Inc (NASDAQ:AGEN) Ratings Coverage

Out of 5 analysts covering Agenus (NASDAQ:AGEN), 4 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. Agenus has been the topic of 8 analyst reports since July 27, 2015 according to StockzIntelligence Inc. On Monday, July 27 the stock rating was maintained by MLV with “Buy”. The rating was downgraded by H.C. Wainwright on Friday, October 28 to “Neutral”. The firm has “Buy” rating given on Friday, March 11 by Maxim Group. The company was maintained on Wednesday, March 9 by JMP Securities. The firm has “Hold” rating by Maxim Group given on Tuesday, October 27. The firm has “Buy” rating by Jefferies given on Friday, July 29. The firm earned “Buy” rating on Wednesday, December 16 by Jefferies. On Thursday, October 27 the stock rating was maintained by Maxim Group with “Buy”.

According to Zacks Investment Research, “Agenus Inc., formerly known as Antigenics Inc., is engaged in the discovery, development and commercialization of immunotherapeutics for the treatment of life threatening and chronic medical conditions. Immunotherapeutics are drugs that work by modulating the immune system to fight diseases. The Company’s product line includes Oncophage vaccine, a patient-specific therapeutic cancer vaccine. The Company is also developing Prophage, patient-specific therapeutic cancer vaccine; QS-21, vaccine adjuvant; and HerpV, a polyvalent off-the-shelf therapeutic heat shock protein-based vaccine for treatment of genital herpes which are all in the clinical testing stages. Agenus Inc. is headquartered in Lexington, Massachusetts.”

Insitutional Activity: The institutional sentiment decreased to 0.8 in 2016 Q2. Its down 0.58, from 1.38 in 2016Q1. The ratio turned negative, as 15 funds sold all Agenus Inc shares owned while 26 reduced positions. 7 funds bought stakes while 26 increased positions. They now own 34.68 million shares or 5.72% less from 36.79 million shares in 2016Q1.
New York State Common Retirement Fund holds 0% or 69,600 shares in its portfolio. Moreover, Credit Suisse Ag has 0% invested in Agenus Inc (NASDAQ:AGEN) for 41,045 shares. Northern Tru Corporation has invested 0% of its portfolio in Agenus Inc (NASDAQ:AGEN). Weiss Multi reported 93,312 shares or 0.03% of all its holdings. Moreover, National Bank & Trust Of America De has 0% invested in Agenus Inc (NASDAQ:AGEN) for 8,887 shares. State Board Of Administration Of Florida Retirement Sys last reported 21,464 shares in the company. California Pub Employees Retirement Systems has 141,853 shares for 0% of their US portfolio. Citadel Advsr Ltd Liability Corporation last reported 0% of its portfolio in the stock. Deutsche Bank & Trust Ag last reported 112,244 shares in the company. Teachers has invested 0% of its portfolio in Agenus Inc (NASDAQ:AGEN). Metropolitan Life Insurance Commerce Ny has invested 0% of its portfolio in Agenus Inc (NASDAQ:AGEN). Victory Mgmt Inc has 0% invested in the company for 3,200 shares. Financial Bank Of Montreal Can holds 0% of its portfolio in Agenus Inc (NASDAQ:AGEN) for 500 shares. Millennium Limited Company has 0.03% invested in the company for 2.95 million shares. Bnp Paribas Arbitrage Sa has invested 0% of its portfolio in Agenus Inc (NASDAQ:AGEN).

Insider Transactions: Since May 5, 2016, the stock had 1 buy, and 0 selling transactions for $188,700 net activity. Shares for $188,700 were bought by WIINBERG ULF on Tuesday, September 6. 100,000 shares were bought by ARMEN GARO H, worth $317,895 on Thursday, May 5. 2,250 shares with value of $6,975 were bought by Baysal Ozer on Thursday, May 5.

More important recent Agenus Inc (NASDAQ:AGEN) news were published by: Fool.com which released: “Why Fret Over Agenus Inc. Q3 Results?” on October 27, 2016, also Fool.com published article titled: “Better Buy: Agenus Inc. vs. Bellicum Pharmaceuticals Inc.”, Prnewswire.com published: “Agenus to Report Third Quarter 2016 Financial Results on October 27, 2016 …” on October 20, 2016. More interesting news about Agenus Inc (NASDAQ:AGEN) was released by: Prnewswire.com and their article: “Agenus Appoints James Gorman, M.D., Ph.D. as Vice President of Strategic …” with publication date: October 18, 2016.

AGEN Company Profile

Agenus Inc. (Agenus), incorporated on November 10, 1999, is an immuno-oncology company. The Firm is engaged in discovering and developing treatments for patients with cancer. The Company’s approaches are driven by platforms and programs, which include antibody discovery platform, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage and AutoSynVax, and saponin vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Firm has a portfolio of programs in various stages of development, including a series of antibodies in discovery and pre-clinical and clinical development, Prophage vaccine, a Heat Shock Protein (HSP) vaccine candidate for a form of brain cancer that has completed Phase II trials, and a number of QS-21 Stimulon-containing vaccine candidates in late stage development. The Firm has programs targeting GITR, OX40, CTLA-4, LAG-3, TIM-3, PD-1, CEACAM1 and other undisclosed targets.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment